Combined oral contraceptives in women with menstrual migraine without aura Vincenzo De Leo, M.D., Valeria Scolaro, M.D., Maria Concetta Musacchio, M.D., Alessandra Di Sabatino, M.D., Giuseppe Morgante, M.D., Antonio Cianci, M.D. Fertility and Sterility Volume 96, Issue 4, Pages 917-920 (October 2011) DOI: 10.1016/j.fertnstert.2011.07.1089 Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions
Figure 1 Participants flowchart. Fertility and Sterility 2011 96, 917-920DOI: (10.1016/j.fertnstert.2011.07.1089) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions
Figure 2 Group A (20 μg of ethinyl E2 + 3 mg of drospirenone in 21 active + 7 placebo pills) and group B (20 μg of ethinyl E2 + 3 mg of drospirenone in 24 active + 4 placebo pills), demonstrated a significant reduction in the intensity and a significant shorter duration of menstrual migraine throughout the study period. Fertility and Sterility 2011 96, 917-920DOI: (10.1016/j.fertnstert.2011.07.1089) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions
Figure 3 Patients in group B reported significant reduction of the intensity and a shorter duration of their menstrual migraine, compared with group A: these improvements appeared during the first treatment cycle and gradually increased until the 3rd month of COC therapy. Fertility and Sterility 2011 96, 917-920DOI: (10.1016/j.fertnstert.2011.07.1089) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions